Showing results (61-70 of 124) with videos related to

Sort By:
Pageof 13
Wellcome Open Research|June 13, 2020
Comparisons of Staphylococcus aureus infection and other outcomes between users of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers: lessons for COVID-19 from a nationwide cohort studyPatrick Bidulka, Masao Iwagami, Kathryn E Mansfield, et al.
Pharmacoepidemiology and Drug Safety|January 8, 2026
Assessment of a Modified High-Dimensional Propensity Score Approach for UK Electronic Health Record Data: Evaluating Upper Gastrointestinal Safety of NSAIDs and COX-2 InhibitorsJohn Tazare, Daniel C Gibbons, Liam Smeeth, et al.
International Journal of Epidemiology|October 19, 2022
Proton pump inhibitors and myocardial infarction: an application of active comparators in a self-controlled case seriesCeline S L Chui, Ka Shing Cheung, Jeremy P Brown, et al.
BMJ Mental Health|May 27, 2026
Infections and severe mental illness: a population-based matched cohort studySharon L Cadogan, Georgia R Gore-Langton, Kathryn E Mansfield, et al.
JAMA Cardiology|August 16, 2023
Association Between Fluoroquinolone Use and Hospitalization With Aortic Aneurysm or Aortic DissectionJeremy P Brown, Kevin Wing, Clémence Leyrat, et al.
Psychological Medicine|December 9, 2024
The role of psychotropics on the associations between extreme temperature and heat-related outcomes among people with mental health conditions: population-based studyAngel Y S Wong, Masao Iwagami, Yuta Taniguchi, et al.
Plos Medicine|August 29, 2024
Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation studyEmma Maud Powell, Usha Gungabissoon, John Tazare, et al.
British Journal of Clinical Pharmacology|January 4, 2021
Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort studyJeremy P Brown, John R Tazare, Elizabeth Williamson, et al.
Pharmacoepidemiology and Drug Safety|January 29, 2022
Transparency of high-dimensional propensity score analyses: Guidance for diagnostics and reportingJohn Tazare, Richard Wyss, Jessica M Franklin, et al.
BJGP Open|April 22, 2026
Potential interactions between SSRIs and DOACs: population-based cohort and case-crossover studyMarco Chau, Charlotte Warren-Gash, Krishnan Bhaskaran, et al.
Pageof 13